Studying Pathways of Resistance in KRAS-driven Cancers

计划入组 58 人 · 首次发布于 2022 年 3 月 9 日

Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

计划入组 150 人 · 首次发布于 2007 年 11 月 1 日

Immunotherapy in Uncommon and 20ins EGFR-mut Lung Cancers

计划入组 627 人 · 首次发布于 2023 年 12 月 11 日

C-4

EGFR antagonists

EGFR-806

ASSO DE RECHERCHE CANCERS GYNECOLOGIQUES

France

Context Therapeutics

United States

Erasca

United States

AstraZeneca Exercises Option for Pinetree's First-in-Class EGFR Degrader in $500M+ Deal

EpiBiologics Raises $107M Series B to Advance Novel EGFR-Targeting Bispecific Antibody EPI-326 into Clinical Trials

Targeted Therapies Transform Stage 4 Lung Cancer from Death Sentence to Chronic Condition